Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

por Mahdi, Haider S., Woodall-Jappe, Mary, Singh, Preeti, Czuczman, Myron S.
Publicado 2023

Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells

por Gu, Juan J., Kaufman, Gregory P., Mavis, Cory, Czuczman, Myron S, Hernand ez-Ilizaliturri, Francisco J.
Publicado 2016

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

por Gu, Juan J., Singh, Anil, Xue, Kai, Mavis, Cory, Barth, Matthew, Yanamadala, Vivek, Lenz, Peter, Grau, Michael, Lenz, Georg, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado 2017

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial

por Xue, Kai, Gu, Juan J., Zhang, Qunling, Liu, Xiaojian, Wang, Jiachen, Li, Xiao-qiu, Luo, Jianfeng, Hernandez, Francisco J., Fernandez, Stanley F., Czuczman, Myron S., Cao, Junning, Hong, Xiaonan, Guo, Ye
Publicado 2016

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

por Lansigan, Frederick, Barak, Ian, Pitcher, Brandelyn, Jung, Sin‐Ho, Cheson, Bruce D., Czuczman, Myron, Martin, Peter, Hsi, Eric, Schöder, Heiko, Smith, Scott, Bartlett, Nancy L., Leonard, John P., Blum, Kristie A.
Publicado 2018

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

por Ogasawara, Ken, Newhall, Kathryn, Maxwell, Stephen E., Dell’Aringa, Justine, Komashko, Vitalina, Kilavuz, Nurgul, Delarue, Richard, Czuczman, Myron, Sternas, Lars, Rose, Shelonitda, Beach, C. L., Novick, Steven, Zhou, Simon, Palmisano, Maria, Li, Yan
Publicado 2019

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

por Casulo, Carla, Santoro, Armando, Cartron, Guillaume, Ando, Kiyoshi, Munoz, Javier, Le Gouill, Steven, Izutsu, Koji, Rule, Simon, Lugtenburg, Pieternella, Ruan, Jia, Arcaini, Luca, Casadebaig, Marie‐Laure, Fox, Brian, Kilavuz, Nurgul, Rettby, Nils, Dell'Aringa, Justine, Taningco, Lilia, Delarue, Richard, Czuczman, Myron, Witzig, Thomas
Publicado 2022

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

por Nowakowski, Grzegorz S., Chiappella, Annalisa, Gascoyne, Randy D., Scott, David W., Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E., Vitolo, Umberto
Publicado 2021